Dr Boccia speaks with ecancer at the 16th International Myeloma Workshop about the CHAMPION-2 study.
The study evaluated different dose levels of carfilzomib in combination with fixed-dose cyclophosphamide and dexamethasone for the treatment of newly diagnosed multiple myeloma (MM).
Carfilzomib is a selective and irreversible second-generation proteasome inhibitor.
Carfilzomib (56 mg/m2) twice weekly combined with cyclophosphamide and dexamethasone had manageable toxicity and was effective for treating patients with newly diagnosed MM.
Carfilzomib is also being trialled in relapsed/refractory myeloma, as discussed by Dr Siegel here.
ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.